Zocor Related Published Studies
Well-designed clinical trials related to Zocor (Simvastatin)
Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. [2008.10.13]
Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. [2008.10]
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. [2008.09.25]
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). [2008.09.01]
Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia. [2008.08.15]
Combination of simvastatin with berberine improves the lipid-lowering efficacy. [2008.08]
Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. [2008.07.16]
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. [2008.07]
Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. [2008.07]
Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. [2008.07]
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. [2008.06]
[Effects of simvastatin on acute-phase protein levels after cardiac surgery] [2008.05.31]
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). [2008.05.15]
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. [2008.05]
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. [2008.04.22]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008.04.21]
Simvastatin with or without ezetimibe in familial hypercholesterolemia. [2008.04.03]
Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study). [2008.04.01]
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. [2008.04]
Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. [2008.04]
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. [2008.03.26]
Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. [2008.03]
Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. [2008.03]
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. [2008.03]
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in Diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). [2008.02.15]
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. [2008.02]
In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. [2008.02]
Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. [2008.01]
Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. [2008.01]
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. [2008.01]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008]
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. [2008]
The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. [2007.12]
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. [2007.12]
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. [2007.12]
Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. [2007.11.01]
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. [2007.11.01]
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques. [2007.11]
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). [2007.10.01]
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study. [2007.10]
Effects of treatment with a commercially available St John's Wort product (Movina(R)) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. [2007.09]
Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. [2007.09]
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. [2007.09]
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. [2007.08.28]
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. [2007.08.28]
Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. [2007.08]
The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study. [2007.08]
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. [2007.07.15]
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. [2007.07]
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. [2007.07]
Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). [2007.06.15]
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. [2007.06.15]
Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine. [2007.06.12]
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. [2007.05]
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. [2007.04.01]
Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. [2007.04]
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. [2007.04]
Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. [2007.03]
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. [2007.03]
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. [2007.02]
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. [2007.02]
Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. [2007.02]
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. [2007.01.23]
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. [2007.01]
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. [2007]
Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. [2007]
Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. [2006.12.15]
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. [2006.12]
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. [2006.12]
Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. [2006.12]
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. [2006.11.07]
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. [2006.11]
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. [2006.10]
Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. [2006.10]
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. [2006.09.09]
The effect of high dose simvastatin on, platelet size in patients with, type 2 diabetes mellitus. [2006.08]
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. [2006.07.25]
Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. [2006.07]
Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). [2006.06]
Validated HPLC-MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. [2006.05.03]
Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. [2006.05]
Effect of systemic administration of simvastatin on retinal circulation. [2006.05]
Comparison of midazolam and simvastatin as cytochrome P450 3A probes. [2006.04]
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. [2006.04]
Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. [2006.04]
Effect of Taizhi'an capsule combined with Simvastatin on hyperlipidemia in diabetic patients. [2006.03]
Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. [2006.03]
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. [2006.03]
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. [2006.02.23]
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. [2006.02]
The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. [2006.02]
In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. [2006.02]
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. [2006.01]
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal] [2006.01]
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. [2006.01]
Simvastatin causes changes in affective processes in elderly volunteers. [2006.01]
The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus. [2006.01]
Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma : a randomised trial. [2006]
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease. [2006]
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. [2005.12]
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. [2005.12]
|
